Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability
Despite considerable efforts to develop medications to treat psychostimulant use disorders, none have proven effective, leaving an underserved patient population and unanswered questions as to what mechanism(s) of action should be targeted for developing
Giancola, JoLynn B.,Bonifazi, Alessandro,Cao, Jianjing,Ku, Therese,Haraczy, Alexandra J.,Lam, Jenny,Rais, Rana,Coggiano, Mark A.,Tanda, Gianluigi,Newman, Amy Hauck
(2020/09/17)
MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN
Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disease where modulation of Myc family proteins is desired. Also disclosed herein are methods of using said compounds and compositions.
-
Paragraph 00188
(2020/09/08)
ATYPICAL INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF
Disclosed herein are a series of modafinil analogue compounds that bind with moderate to high affinity to the dopamine (DA) transporter (DAT) and several analogues also having affinity for the serotonin (5-HT) transporter (SERT) and/or sigma-1 receptor. E
-
Paragraph 0115
(2019/05/30)
More Articles about upstream products of 1152430-26-6